Using a prospective longitudinal study design, this study evaluated peripheral blood parameters pre-aPBSCT and on day 100, at 6 months, 1 year, 2 years, and 3 years in 304 patients treated with aPBSCT. The relation between peripheral blood parameters and subsequent development of t-MN was examined, and nomograms were developed to identify patients at risk for t-MN.
Twenty-one patients developed t-MN at a median of 1.95 years post-aPBSCT. Hemoglobin, hematocrit, white blood cell, and platelet counts were lower among patients who developed t-MN compared to those who did not; these differences appeared soon after aPBSCT, persisted, and preceded development of t-MN. Older age at aPBSCT (hazard ratio [HR]per_year_increase = 1.08, P = .007), exposure to total body irradiation (TBI) (HR = 2.90, P = .04), and low 100-day platelet count (HRincrease_per_unit_decline_in_PLT = 1.01, P = .002) predicted subsequent t-MN. These parameters and primary diagnosis allowed identification of patients at high risk of t-MN (eg, an HL patient undergoing aPBSCT at the age of 70 years with TBI and with a day 100 PLT between 100,000 and 150,000 would have a 62% probability of developing t-MN at 6 years post-aPBSCT).
Abnormalities in peripheral blood parameters can identify patients at high risk for t-MN after aPBSCT for HL or NHL, allowing opportunities to personalize close surveillance and possible disease-modifying interventions.
使用前瞻性纵向研究设计,这项研究评估了aPBSCT前和第100天,6个月时的外周血参数,1年,2年,304例接受aPBSCT治疗的患者为3年。检查了外周血参数与随后的t-MN发展之间的关系,并绘制列线图以鉴定有t-MN风险的患者。
21名患者在aPBSCT后1.95年出现t-MN。血红蛋白,血细胞比容,白细胞,与未发生t-MN的患者相比,发生t-MN的患者的血小板计数较低;这些差异在aPBSCT后不久出现,坚持,并先于t-MN的发展。aPBSCT的年龄较大(每年增加的危险比[HR]=1.08,P=.007),全身照射(TBI)(HR=2.90,P=.04),和低100天血小板计数(HRincrease_per_unit_declines_in_PLT=1.01,P=0.002)预测随后的t-MN。这些参数和初步诊断允许识别t-MN高风险患者(例如,接受aPBSCT的HL患者,年龄为70岁,患有TBI,第100天PLT在100,000至150,000之间,在aPBSCT后6年发生t-MN的概率为62%).
外周血参数异常可以识别HL或NHLaPBSCT后t-MN高危患者,允许个性化密切监测和可能的疾病改善干预措施的机会。